InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.68% | 7.59% | -10.36% | 40.22% | -44.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.68% | 7.59% | -10.36% | 40.22% | -44.48% |
| Cost of Revenue | -10.88% | 22.98% | -28.96% | -12.42% | 10.30% |
| Gross Profit | 23.73% | -39.34% | 42.21% | 2,227.36% | -70.32% |
| SG&A Expenses | 27.93% | -3.28% | 13.90% | 9.49% | 24.98% |
| Depreciation & Amortization | -3.65% | -4.56% | -3.62% | -0.36% | 2.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.41% | 13.75% | 12.67% | -14.39% | 16.44% |
| Operating Income | 8.31% | -17.77% | -29.42% | 33.15% | -289.11% |
| Income Before Tax | 7.37% | -23.10% | -74.20% | 33.86% | -473.56% |
| Income Tax Expenses | -- | -- | -- | -- | 294.44% |
| Earnings from Continuing Operations | 7.71% | -23.10% | -74.20% | 33.86% | -472.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.71% | -23.10% | -74.20% | 33.86% | -472.61% |
| EBIT | 8.31% | -17.77% | -29.42% | 33.15% | -289.11% |
| EBITDA | 8.43% | -18.47% | -30.52% | 33.85% | -322.26% |
| EPS Basic | 70.32% | 46.01% | 1.71% | 82.25% | -98.36% |
| Normalized Basic EPS | 70.21% | 46.01% | 1.71% | 82.25% | -98.69% |
| EPS Diluted | 70.32% | 46.01% | 1.71% | 82.25% | -98.36% |
| Normalized Diluted EPS | 70.21% | 46.01% | 1.71% | 82.25% | -98.69% |
| Average Basic Shares Outstanding | 210.94% | 128.05% | 77.20% | 272.66% | 188.57% |
| Average Diluted Shares Outstanding | 210.94% | 128.05% | 77.20% | 272.66% | 188.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |